M. Pink

发表

Bradykinin modulation of tumor vasculature: I. Activation of B2 receptors increases delivery of chemotherapeutic agents into solid peripheral tumors, enhancing their efficacy.

R. Bartus, D. Emerich, R. Dean, 2001, The Journal of pharmacology and experimental therapeutics.

The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activity in vivo

James R. Porter, K. West, J. Adams, 2009, Molecular Cancer Therapeutics.

Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate.

V. Palombella, Johan A. Pradeilles, Ann M. Rowley, 2016, ACS medicinal chemistry letters.

Intravenous Cereport (RMP-7) Enhances Delivery of Hydrophilic Chemotherapeutics and Increases Survival in Rats with Metastatic Tumors in the Brain

R. Bartus, D. Emerich, R. Dean, 2000, Pharmaceutical Research.

Central analgesic actions of loperamide following transient permeation of the blood brain barrier with Cereport™ (RMP-7) 1 Published on the World Wide Web on 30 June 1998. 1

F. Bloom, R. Bartus, D. Emerich, 1998, Brain Research.

Enhanced delivery of carboplatin into brain tumours with intravenous CereportTM (RMP-7): dramatic differences and insight gained from dosing parameters

R. Bartus, B. S. Kim, D. Emerich, 1999, British Journal of Cancer.

The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies

J. Kutok, E. Murphy, J. Proctor, 2018, PloS one.

Anti-Tumor Activity of IPI-504, a Novel Hsp90 Inhibitor in Multiple Myeloma.

J. Sydor, M. Foley, C. Mitsiades, 2004 .

Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926).

Jeanne A. Ferguson, J. Sydor, J. Adams, 2009, Journal of medicinal chemistry.

PI3Kγ is a molecular switch that controls immune suppression

Philippe Foubert, Kelly A. Frazer, Hongying Li, 2016, Nature.

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells

J. Kutok, J. Wolchok, Sujata Sharma, 2016, Nature.

Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90

Jie Ge, James R. Porter, J. Sydor, 2006, Proceedings of the National Academy of Sciences.

PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models.

Bonnie Tillotson, James R. Porter, Pingda Ren, 2013, Chemistry & biology.

A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing.

W. Harrington, William E. Salomon, L. Shaw, 2018, Cell reports.

Abstract 376: Combination of duvelisib with either ibrutinib or dexamethasone prevents mTOR-dependent feedback in aggressive B-cell lymphoma cell lines

J. Kutok, E. Murphy, J. Proctor, 2016 .

High throughput in vitro combination sensitivity screen in hematologic malignancies with the phosphoinositide-3 kinase (PI3K)-{delta},{gamma} inhibitor, duvelisib.

R. Rickles, J. Leverson, Jill M. Grenier, 2015 .

Bradykinin modulation of tumor vasculature: II. activation of nitric oxide and phospholipase A2/prostaglandin signaling pathways synergistically modifies vascular physiology and morphology to enhance delivery of chemotherapeutic agents to tumors.

R. Bartus, D. Emerich, R. Dean, 2001, The Journal of pharmacology and experimental therapeutics.

570 POSTER Activity of IPI-926, a novel inhibitor of the HH pathway, in subcutaneous and orthotopically implanted xenograft tumors that express SHH ligand

J. Sydor, V. Palombella, Z. Oaks, 2008 .

Corrigendum: PI3Kγ is a molecular switch that controls immune suppression

A. V. Nguyen, K. Frazer, J. Kutok, 2016, Nature.